Kurzfassung

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major
Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular
Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)